CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Opticell Agdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02642679
NCT02642679N/ACompleted
CompareCT.gov

Evaluation of Opticell Ag (Chitosan Based Dressing) on Split-Thickness Skin Graft (STSG) Donor Sites in Adult Subjects

Brigham and Women's Hospital·interventional·Posted Dec 30, 2015·Updated Dec 8, 2017

In Brief

A clinical study evaluating Opticell Ag for Split-thickness Skin Graft Donor Sites. Completed, enrolled 19 participants.

Detailed Summary

The purpose of this single center, prospective case series is to evaluate the effective management of split-thickness skin graft donor site wounds using Opticell Ag (Chitosan-based dressing).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSplit-thickness Skin Graft Donor Sites
Countries--
CollaboratorsMedline Industries

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 30, 2015
Enrollment StartJan 1, 2016
Primary CompletionOct 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.5 years ago

Interventions

Opticell Agdevice

Opticell Ag+ applied to STSG donor site